Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Spivack, Phyllis G. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08008319
ABSTRACT:
The invention relates to treating colorectal polyps and precancercerous colorectal changes by topical administration of immunomodulating drugs of the imidazoquinoline family, such as imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine), resiquimod (4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), sotirimod (2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine).
REFERENCES:
patent: 2004/0092583 (2004-05-01), Shanahan-Prendergast
patent: 2006/0193789 (2006-08-01), Tamarkin et al.
Domingo E. Galliano, Jr., MD, Charlotte County Edition/Spring, 2008/Florida Health Care News/ p. 11.
The Merck Manual, 17thedition, pp. 326-327 (1999).
Sidky Y. A. et al.: “Inhibition of Murine Tumor Growth by an Interferon-Inducing Imidazoquinolinamine” Cancer Research, vol. 52, No. 13, 1992, pp. 3528-3533.
Fleshner Phillip et al.: “Practice Paramaters for Anal Squamous Neoplasms” Nov. 21, 2007, Diseases of the Colon & Rectum, Springer-Verlag, NE, pp. 2-9.
Lipka E. et al.: “Evaluation of imiquimod and analogues with respect to their oral delivery potential” Proceedings of the Int'l. Symp. Control. Rel. Bioact. Mater., 1997 US, No. 24, 1997, pp. 337-338.
Carrasco Daniel et al.: “Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions.” Journal of the American Academy of Dermatology, vol. 47, No. 4 Suppl, Oct. 2002, pp. 5212-5216.
Diakomanolis Emmanuel et al.: “Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream.” The New England Journal of Medicine, Aug. 1, 2002, vol. 347, No. 5, p. 374.
Pfenninger John L. et al.: “Common anorectal conditions” Obstetrics and Gynecology, vol. 98, No. 6, Dec. 2001, pp. 1130-1139.
International Search Report dated Apr. 1, 2009, issued in related International Application No. PCT/EP2008/011088.
Burmer, G. C. et al., “Neoplastic Progression Ulcerative Colitis: Histology, DNA Content, and Loss of a p53 Allele”,Gastroeterology, vol. 103(5), p. 1602-10, Nov 1992.
Hussain, S.P. et al, “Increased p53 Mutation Load in Noncancerous Colon Tissue from Ulcerative Colitis: A Cancer-Prone Chronic Inflammatory Disease”,Cancer Research, vol. 60, p. 3333-3337, Jul. 1, 2000.
Van Den Berg, F.M. et al., “Expression of the Nuclear Oncogene p53 in Colon Tumours”,Journal of Pathology, vol. 157, p. 193-199, 1989.
Maus Joachim
Petzold Ursula
Szelenyi Istvan
Haddaway Keith G.
MEDA Pharma GmbH & Co. KG
Spivack Phyllis G.
Venable LLP
LandOfFree
Treatment of colorectal polyps with imidazoquinoline... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of colorectal polyps with imidazoquinoline..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of colorectal polyps with imidazoquinoline... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2777166